Esophageal Diseases Clinical Trial
Official title:
Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered
NCT number | NCT05182255 |
Other study ID # | MDR-2054 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 28, 2022 |
Est. completion date | December 2024 |
The aim of this post-market clinical follow-up study is to evaluate the continued safety and performance of the marketed Evolution® Esophageal Stent System (Partially- and Fully Covered).
Status | Recruiting |
Enrollment | 313 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1: Patient has had at least one of the following stents implanted between 1st January 2018 and 31st December 2020*: - Evolution® Esophageal Stent System-Partially Covered - Evolution® Esophageal Stent System-Fully Covered - Evolution® Esophageal Stent System-Fully Covered Exclusion Criteria: 1: Deceased retrospective patient who has set post-mortem instruction against processing of his/her health data 2. Patient or his/her legally authorized representative objects to collection and processing of his/her data, or not willing to sign not willing to sign an Informed consent, if it is required by the local EC committee. There may be local exemptions where consent is not a requirement or non-objection letters may replace informed consent processes. |
Country | Name | City | State |
---|---|---|---|
Germany | Klinikum Altenburg | Altenburg | |
Germany | Universitatsklinikum Augsburg | Augsburg | |
Germany | Evangelisches Krankenhaus Düsseldorf | Düsseldorf | |
Spain | Hospital Universitario de Salamanca | Salamanca | ESP |
United Kingdom | University College London | London |
Lead Sponsor | Collaborator |
---|---|
Cook Research Incorporated |
Germany, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with clinically relevant device migration | Clinically relevant device migration is defined as stent migration requiring replacement of the stent due to degree of migration as well as clinical symptoms (i.e. an inability of the stent to perform its intended function). | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054933 -
Ultrasound Capsule Endoscopy for Esophagus Examination
|
N/A | |
Completed |
NCT04090554 -
Cytosponge™ Feasibility Study in Tanzania
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Recruiting |
NCT04481100 -
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03859557 -
The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
|
||
Completed |
NCT00977678 -
Drop in Gastroscopy - Experience After 9 Months
|
N/A | |
Recruiting |
NCT04068480 -
Esophageal and Gastric Diseases With Robotically Controlled Magnetic Capsule Endoscopy
|
||
Completed |
NCT00874263 -
Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies
|
N/A | |
Terminated |
NCT00442507 -
Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
|
Phase 2 | |
Recruiting |
NCT03832959 -
Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study.
|
N/A | |
Withdrawn |
NCT02569073 -
Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain
|
Phase 4 | |
Recruiting |
NCT05252078 -
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
|
Phase 2 | |
Recruiting |
NCT00260585 -
Esophageal Cancer Risk Registry
|
||
Completed |
NCT03187314 -
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT05004155 -
Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
|
||
Recruiting |
NCT05469152 -
Detachable String Magnetically Controlled Capsule Endoscopy for Follow-up of Patients With Esophageal Diseases
|
N/A | |
Recruiting |
NCT05877300 -
Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement
|
Phase 1 | |
Recruiting |
NCT03267355 -
Indications and Outcomes of Endoscopic Ultrasound in Tanta
|
N/A | |
Recruiting |
NCT00939263 -
Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index
|
N/A |